AMARIN CORP PLC\UK
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
AMRN$11.75+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)(1) For a list of the financial statements included herein, see Index to Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K.
(2) Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.
(3) Exhibits
The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index below. The exhibits listed in the Exhibit Index are incorporated by reference herein.
(b) Exhibit Index
| Exhibit | Incorporated by Reference Herein | ||
| Number | Description | Form | Date |
| 3.1 | Articles of Association of the Company | Current Report on Form 8-K filed with the Commission on April 22, 2024, as Exhibit 3.1 | April 22, 2024 |
| 4.1 | Form of Second Amended and Restated Deposit Agreement among Amarin Corporation plc, JPMorgan Chase Bank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners from time to time of American Depositary Receipts (“ADRs”) issued thereunder, including the Form of ADR attached as Exhibit A thereto | Registration Statement on Form F-6, Exhibit (a) | July 23, 2025 |
| 4.2 | Form of Ordinary Share certificate | Annual Report on Form 20-F for the year ended December 31, 2002, as Exhibit 2.4 | April 24, 2003 |
| 4.3 | Form of American Depositary Receipt evidencing ADSs | Registration Statement on Form F-6, Exhibit (a) | July 23, 2025 |
| 4.4 | Description of Registrant’s Securities | Filed herewith | |
| 10.1 | The Company 2011 Stock Option Plan* | Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011, as Exhibit 10.4 | August 9, 2011 |
| 10.2 | Amendment No. 1 to 2011 Stock Option Incentive Plan* | Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2012, as Exhibit 10.1 | August 8, 2012 |
| 10.3 | Amendment No. 2 to 2011 Stock Option Incentive Plan* | Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2012, as Exhibit 10.2 | August 8, 2012 |
| 10.4 | Amendment No. 3 to 2011 Stock Option and Incentive Plan* | Annual Report on Form 10-K for the year ended December 31, 2012, as Exhibit 10.5 | February 28, 2013 |
| 10.5 | Amendment No. 4 to 2011 Stock Option and Incentive Plan* | Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2015, as Exhibit 4.1 | August 6, 2015 |
| 10.6 | Amendment No. 5 to 2011 Stock Option and Incentive Plan* | Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2015, as Exhibit 4.2 | August 6, 2015 |
| 10.7 | Amendment No.6 to 2011 Stock Incentive Plan* | Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2017, as Exhibit 4.1 | August 2, 2017 |
| 10.8 | Form of Incentive Stock Option Award Agreement* | Annual Report on Form 10-K for the year ended December 31, 2011, as Exhibit 10.3 | February 29, 2012 |
| 10.9 | Form of Non-Qualified Stock Option Award Agreement* | Annual Report on Form 10-K for the year ended December 31, 2011, as Exhibit 10.4 | February 29, 2012 |
| 10.10 | Form of Restricted Stock Unit Award Agreement* | Annual Report on Form 10-K for the year ended December 31, 2011, as Exhibit 10.5 | February 29, 2012 |
| 10.11 | 2017 Employee Stock Purchase Plan* | Annual Report on Form 10-K for the year ended December 31, 2017, as Exhibit 10.64 | February 27, 2018 |
| 10.12 | 2020 Stock Incentive Plan* | Current Report on Form 8-K dated July 13, 2020, as Exhibit 10.1 | July 14, 2020 |
| 10.13 | Amendment No. 1 to 2020 Stock Incentive Plan* | Current Report on Form 8-K dated June 27, 2022, as Exhibit 10.2 | June 30, 2022 |
| 10.14 | Form of Incentive Stock Option Award Agreement* | Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, as Exhibit 10.2 | November 5, 2020 |
| 10.15 | Form of Non-Qualified Stock Option Award Agreements* | Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, as Exhibit 10.3 | November 5, 2020 |
| 10.16 | Form of Restricted Stock Unit Award Agreement* | Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, as Exhibit 10.3 | August 3, 2022 |
| 10.17 | Form of Non-Qualified Stock Option for Non-Employee Director Award Agreement* | Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, as Exhibit 10.5 | November 5, 2020 |
| 10.18 | Form of Deferred Restricted Stock Unit Award Agreement* | Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, as Exhibit 10.2 | August 3, 2022 |
| 10.19 | Amarin Corporation plc Executive Severance and Change of Control Plan* | Current Report on Form 8-K dated January 28, 2021, as Exhibit 10.1 | January 29, 2021 |
| 10.20 | Letter Agreement with Steve Ketchum, dated February 8, 2012* | Registration Statement on Form F-1, as Exhibit 10.1 | February 28, 2012 |
| 10.21 | Amendment, dated July 6, 2015, to Letter Agreement with Steven Ketchum, dated February 8, 2012* | Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2015, as Exhibit 10.2 | August 6, 2015 |
| 10.22 | Development, Commercialization and Supply Agreement dated February 26, 2015, by and between Amarin Pharmaceuticals Ireland Limited, Amarin Pharma, Inc. and Eddingpharm (Asia) Macao Commercial Offshore Limited†† | Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2015, as Exhibit 10.1 | May 8, 2015 |
| 10.23 | Distribution Agreement, dated March 8, 2016, by and among Biologix FZCo, Amarin Pharmaceuticals Ireland Limited and Amarin Pharma, Inc. †† | Annual Report on Form 10-K for the year ended December 31, 2017, as Exhibit 10.67 | February 27, 2018 |
| 10.24 | Development, Commercialization and Supply Agreement, dated September 25, 2017, by and among Amarin Pharmaceuticals Ireland Limited, Amarin Pharma, Inc. and HLS Therapeutics Inc. †† | Annual Report on Form 10-K for the year ended December 31, 2017, as Exhibit 10.68 | February 27, 2018 |
| 10.25 | Amendment No. 2 to the Amarin Corporation plc 2020 Stock Incentive Plan | Current Report on Form 8-K filed with the Commission on July 25, 2023, as Exhibit 10.2 | July 25, 2023 |
| 10.26 | Offer Letter with Jonathan Provoost, dated October 9, 2023* | Annual Report on Form 10-K filed with the Commission for the year ended December 31, 2023, as Exhibit 10.43 | February 29, 2024 |
| 10.27 | Amendment No. 3 to the Amarin Corporation plc 2020 Stock Incentive Plan | Current Report on Form 8-K filed with the Commission on April 22, 2024, as Exhibit 10.2 | April 22, 2024 |
| 10.28 | CEO Employment Agreement, dated July 25, 2024, by and between Amarin Corporation plc and Aaron Berg. | Current Report on Form 8-K filed with the Commission on July 29, 2024, as Exhibit 10.1 | July 29, 2024 |
| 10.29 | License and Supply Agreement, dated June 20, 2025, by and between Amarin Pharmaceuticals Ireland Limited and Recordati Industria Chimica e Farmaceutica S.p.A.** | Current Report on Form 8-K filed with the Commission on June 24, 2025, as Exhibit 10.1 | June 24, 2025 |
| 10.30 | Amended and Restated Non-Employee Director Compensation Policy | Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, as Exhibit 10.2 | July 30, 2025 |
| 10.31 | Form of Deed of Indemnity* | Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, as Exhibit 10.3 | July 30, 2025 |
| 10.32 | Employment Agreement, between David Keenan and Amarin Pharmaceuticals Ireland Limited, dated February 25, 2022*† | Current Report on Form 8-K filed with the Commission on October 22, 2025, as Exhibit 10.1 | October 22, 2025 |
| 10.33 | First Amendment to the Employment Agreement, between David Keenan and Amarin Pharmaceuticals Ireland Limited, dated July 17, 2023*† | Current Report on Form 8-K filed with the Commission on October 22, 2025, as Exhibit 10.2 | October 22, 2025 |
| 10.34 | Second Amendment to the Employment Agreement, between David Keenan and Amarin Pharmaceuticals Ireland Limited, dated October 6, 2025*† | Current Report on Form 8-K filed with the Commission on October 22, 2025, as Exhibit 10.3 | October 22, 2025 |
| 19.1 | Insider Trading and Disclosure Policy | Annual Report on Form 10-K filed with the Commission for the year ended December 31, 2024, as Exhibit 19.1 | March 12, 2025 |
| 19.2 | Special Trading Procedures for Insiders | Annual Report on Form 10-K filed with the Commission for the year ended December 31, 2024, as Exhibit 19.2 | March 12, 2025 |
| 21.1 | List of Subsidiaries | Filed herewith | |
| 23.1 | Consent of Independent Registered Public Accounting Firm | Filed herewith | |
| 24.1 | Power of Attorney | Included on the signature page(s) hereto | |
| 31.1 | Certification of President and Chief Executive Officer (Principal Executive Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002 | Filed herewith | |
| 31.2 | Certification of Senior Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002 | Filed herewith | |
| 32.1 | Certification of President and Chief Executive Officer (Principal Executive Officer) and Senior Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) pursuant to Section 906 of Sarbanes-Oxley Act of 2002 | Filed herewith | |
| 97.1 | Compensation Recovery Plan | Annual Report on Form 10-K filed with the Commission for the year ended December 31, 2024, as Exhibit 97.1 | March 12, 2025 |
| 101.INS | Inline XBRL Instance Document | Filed herewith | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema with Embedded Linkbases Document | Filed herewith |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibit 101.) | Filed herewith |
- Management contract or compensatory plan or arrangement.
** Portions omitted pursuant to Item 601(b)(10) of Regulation S-K. The Company will supplementally furnish an unredacted copy of the exhibit upon request by Securities and Exchange Commission.
† Certain personal information in this exhibit has been omitted in accordance with Regulation S-K Item 601(a)(6).
†† Confidential treatment has been granted with respect to portions of this exhibit pursuant to an application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. A complete copy of this exhibit, including the redacted terms, has been separately filed with the Securities and Exchange Commission.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.